Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention

Abstract Background Migraine is a leading cause of disability worldwide, impairing quality of life and productivity. Preventive therapies aim to reduce attack frequency, severity and the need for acute medications. Oral atogepant (60 mg), a calcitonin gene-related peptide (CGRP) receptor antagonist,...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Simona Guerzoni, Lanfranco Pellesi, Lisa Giannessi, Flavia Lo Castro, Maria Chiara Olivieri, Luca Degli Esposti, Francesca Gandolfi
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2026-06-01
Serier:	The Journal of Headache and Pain
Fag:	CGRP Gepants Headache Medication-overuse headache Pain
Online adgang:	https://doi.org/10.1186/s10194-026-02434-8
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!